Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

dc.contributor.authorid0000-0002-1273-1674
dc.contributor.coauthorBilici, Ahmet
dc.contributor.coauthorOlmez, Omer Fatih
dc.contributor.coauthorKaplan, Muhammed Ali
dc.contributor.coauthorOksuzoglu, Berna
dc.contributor.coauthorSezer, Ahmet
dc.contributor.coauthorKaradurmus, Nuri
dc.contributor.coauthorCubukcu, Erdem
dc.contributor.coauthorSendur, Mehmet Ali Nahit
dc.contributor.coauthorAksoy, Sercan
dc.contributor.coauthorErdem, Dilek
dc.contributor.coauthorBasaran, Gul
dc.contributor.coauthorCakar, Burcu
dc.contributor.coauthorShbair, Abdallah T. M.
dc.contributor.coauthorArslan, Cagatay
dc.contributor.coauthorSumbul, Ahmet Taner
dc.contributor.coauthorSezgin Goksu, Sema
dc.contributor.coauthorKaradag, Ibrahim
dc.contributor.coauthorCicin, Irfan
dc.contributor.coauthorGumus, Mahmut
dc.contributor.coauthorHarputluoglu, Hakan
dc.contributor.coauthorDemirci, Umut
dc.contributor.departmentN/A
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid202015
dc.date.accessioned2025-01-19T10:34:26Z
dc.date.issued2023
dc.description.abstractAimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccessBronze
dc.description.publisherscopeInternational
dc.description.volume62
dc.identifier.doi10.1080/0284186X.2023.2202330
dc.identifier.eissn1651-226X
dc.identifier.issn0284-186X
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85153495962
dc.identifier.urihttps://doi.org/10.1080/0284186X.2023.2202330
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26769
dc.identifier.wos971681800001
dc.keywordsHER2 protein positive
dc.keywordsBreast cancer
dc.keywordsNeoadjuvant treatment
dc.keywordsPertuzumab
dc.keywordsTrastuzumab
dc.keywordsEvent-free survival
dc.keywordsRelapse
dc.keywordsReal-word evidence
dc.languageen
dc.publisherTaylor and Francis Ltd
dc.sourceActa Oncologica
dc.subjectOncology
dc.titleImpact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
dc.typeJournal Article

Files